Virax Biolabs Group Secures $5 Million in Private Placement Funding

On December 3, 2025, Virax Biolabs Group Limited, trading under the ticker symbol VRAX on Nasdaq, proclaimed its latest move to advance immunology research and diagnostics through a substantial financial boost. The company has entered into definitive agreements to facilitate the sale of 12,500,000 ordinary shares, along with preferred investment options aimed at acquiring the same number of shares. Notably, the shares are priced at $0.40 each, forming the backbone of a $5 million private placement.

The preferred investment options allow for immediate exercise at the aforementioned price and extend over a five-year period starting from the effective date of the Initial Registration Statement. H.C. Wainwright & Co. is tasked with acting as the exclusive placement agent for this offering.

The impending transaction is projected to yield gross proceeds of $5 million prior to any deductions related to agent fees or other expenses. Virax intends to utilize these funds for working capital purposes, bolstering its operational capabilities and increasing its engagement in immunological advancements. This private placement is expected to finalize around December 4, 2025, pending the completion of customary closing conditions.

It's critical to note that this stock offer is being conducted in a manner not considered a public offering. As a result, the securities will not be registered in accordance with the Securities Act of 1933, nor applicable state securities laws, thus restricting the possibility for resale to investors without meeting specific registration or exemption criteria.

Virax has also committed, under its agreement with investors, to file an initial registration statement with the SEC aimed at covering the potential resale of the shares issued in this deal. This statement is set to be processed for approval promptly, ideally within 45 days, in the event a full review is necessitated by the SEC.

Additionally, Virax has agreed upon the closing to revise the exercise price of prior Series A and B Preferred Investment Options issued to investors earlier in 2023. This revision aligns with the new offering's pricing and will extend the options' expiration to match the five-year term from the Initial Registration Statement's effective date.

This press release does not serve as a solicitation or offer to sell any securities nor does it aim to invite offers for purchases outside jurisdictions where such an offer would breach legal stipulations prior to necessary registrations or qualifications under state securities laws.

About Virax Biolabs Group Limited

Virax Biolabs operates as an innovative biotechnology entity that leverages advanced technology for immune response detection and viral disease diagnostics. The company is particularly engaged in developing T cell-based testing methods, aspiring to create a unique immunological profiling platform. This technology is expected to hold substantial promise in diagnosing and potentially treating post-acute infection syndromes, such as Long COVID, along with other chronic conditions that are manifestations of immune system disorders.

For more information concerning Virax Biolabs Group, interested parties can visit their official website at www.viraxbiolabs.com.

Safe Harbor Statement

This announcement includes forward-looking statements surrounding potential future events and company performance. The expectations articulated here are based on current data available and may differ from actual results, influenced by various unpredicted factors and market conditions. Prospective investors should consider these uncertainties and refrain from relying solely on these future projections when making decisions.

In summary, Virax Biolabs' recent actions serve as a significant step toward enhancing its funding and broadening its research initiatives in the immunology domain. The secured capital positions the company favorably to tackle pressing health concerns while facilitating the growth of its diagnostic capabilities.